Asplenia

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
2 Unique IMPs
0 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Vaccine 2 substances
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    NEISSERIA MENINGITIDIS GROUP B FHBP PROTEIN SUBFAMILY A, NEISSERIA MENINGITIDIS GROUP B FHBP PROTEIN SUBFAMILY B; RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE
    2024-513649-35-00 1 country 2022 n=84
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Assistance Publique Hopitaux De Paris Academic 1 Phase III 0
New trials by year
2022
1
← All indication landscapes